Cough And Cold Symptoms, Some Coming From Omicron, Sound Like Seasonal Rebound To Perrigo
Consumer Health Product Firm Notes Potential Sales Impact From Russia’s Invasion Of Ukraine
Executive Summary
Sales growth generated in October-December period and growing incidences of flu and cough/cold symptoms are harbingers for Perrigo in 2022. Sales during January and February in Russia and Ukraine tracked with $10m to $15m operating income firm anticipates there for 2022, “but it's really too early to estimate the potential full-year impact,” CEO Murray Kessler says.
You may also be interested in...
Strongest US Cough/Cold Season In 10 Years Likely
Increasing numbers cough/cold drug prescriptions combined with consumers’ waning interest in flu vaccines point to 2022-2023 season rivaling decade-high levels from 2017-18 and to retailers boosting inventories through year-end, Raymond James analysts say.
SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options
FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages.
Silcock’s Work As Perrigo CFO Is Done With Firm Transitioned Entirely To Self-Care
With Raymond Silcock’s work at Perrigo linked to CEO Murray Kessler’s time with the firm and with the two working together previously as CFO and CEO at a tobacco firm, whether Kessler continues at the helm could become a topic of shareholder interest.